C. Vogel

D. Castro, H. Burris, C. Vogel, 1998, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer.

E. Perez, C. Vogel, D. Irwin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter P hase I I T rial o f W eekly P aclitaxel i n W omen With M etastatic B reast C ancer

E. Perez, C. Vogel, D. Irwin, 2001 .

Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting.

C. Vogel, P. Wiernik, C. Holroyde, 1991, Journal of pain and symptom management.

Current status of salvage chemotherapy for refractory advanced breast cancer

C. Vogel, 1996 .

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

B. Weber, L. Hutchins, C. Vogel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly Paclitaxel in Women Age 65 and Above with Metastatic Breast Cancer*

E. Perez, C. Vogel, D. Irwin, 2002, Breast Cancer Research and Treatment.

Adjuvant systemic therapy of primary breast cancer

C. Vogel, 1988 .

Highlights in metastatic breast cancer from the 2011 San Antonio Breast Cancer Symposium (SABCS).

C. Vogel, 2012, Clinical advances in hematology & oncology : H&O.

Reply to R.S. Mehta et al

C. Perou, T. Nielsen, M. Cheang, 2009 .

Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.

C. Vogel, J. Hohneker, L. Lacerna, 2004, The oncologist.

Hepatitis-associated antigen and antibody in hepatocellular carcinoma: results of a continuing study.

C. Vogel, P. Anthony, L. Barker, 1972, Journal of the National Cancer Institute.

Systemic therapy of breast cancer--1985.

C. Vogel, 1985, Seminars in oncology nursing.

Immunological effects of BCG in malignant melanoma: two modes of administration compared.

A. Bluming, C. Vogel, J. Ziegler, 1972, Annals of internal medicine.

Effect of surgical and chemotherapeutic treatment on alpha‐fetoprotein levels in patients with hepatocellular carcinoma

T. Waldmann, C. Vogel, A. Primack, 1976, Cancer.

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

J. Doroshow, J. Bennett, C. Vogel, 1985, Investigational New Drugs.

A phase i study of 4′‐0‐tetrahydropyranyladriamycin: Clinical pharmacology and pharmacokinetics

C. Vogel, N. Savaraj, L. Feun, 1990, Cancer.

Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial

M. Blackstein, C. Vogel, A. Melemed, 2002, Oncology.

Management of locally advanced breast cancer (stage III): a review.

C. Vogel, E. Davila, 1984, International advances in surgical oncology.

Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1).

L. Amler, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

S. Franco, C. Vogel, E. Tan-chiu, 2004, Breast Cancer Research and Treatment.

Erratum: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials (Cancer (1998) 83 (1142-1152))

A. Howell, A. Buzdar, C. Blomqvist, 1999 .

Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

L. Hutchins, C. Vogel, S. Jones, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.

D. Campos, J. R. Pereira, C. Vogel, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.

S. Raab, C. Vogel, J. Carpenter, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

A. Callegaro, G. Curigliano, M. Campone, 2016, Breast Cancer Research and Treatment.

Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.

J. Mackey, C. Vogel, Miguel Martín, 2005, JAMA.

Hormonal approaches to breast cancer treatment and prevention: an overview.

C. Vogel, 1996, Seminars in oncology.

Secretion of methotrexate into human milk.

C. Vogel, D. Johns, P. Leighton, 1972, American journal of obstetrics and gynecology.

A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States

C. Vogel, J. Ziegler, P. Anthony, 1977, Cancer.

International symposium on hepatocellular carcinoma—kampala, uganda (July 1971)

C. Vogel, C. Linsell, 1972 .

Serum alpha‐fetoprotein in 184 ugandan patients with hepatocellular carcinoma. Clinical, laboratory, and histopathologic correlations

C. Vogel, P. Carbone, P. Anthony, 1974, Cancer.

L. Fallowfield, Y. Fujiwara, J. Jassem, 2012, Clinical Cancer Research.

Evaluation of human chorionic gonadotropin and alpha fetoprotein in benign and malignant testicular disorders.

T. Waldmann, C. Vogel, K. Walton, 1978, Surgery, gynecology & obstetrics.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

J. Sparano, C. Vogel, N. Iannotti, 2013, Breast Cancer Research and Treatment.

A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.

A. Buzdar, C. Vogel, J. Wolter, 1997, Cancer.

Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.

C. Vogel, J. Denefrio, 1978, Cancer treatment reports.

A review of vinorelbine in the treatment of breast cancer.

C. Vogel, G. Domenech, 2001, Clinical breast cancer.

Efficacy of trastuzumab.

C. Vogel, L. Reyno, J. Reddy, 2005, Cancer research.

Final 5‐year results of Z‐FAST trial

E. Perez, L. Bosserman, C. Vogel, 2012, Cancer.

When Can a Salvage Therapy (T-DM1) Take the Lead?

C. Vogel, R. Mahtani, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival after first recurrence of breast cancer. The miami experience

S. Hilsenbeck, C. Vogel, S. Azevedo, 1992, Cancer.

A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer

C. Vogel, T. Ambros, A. Montero, 2014, Breast Cancer Research and Treatment.

Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma.

C. Vogel, P. Anthony, L. Barker, 1970, Lancet.

Kaposi's sarcoma: a new model in the search for viruses associated with human malignancies.

C. Vogel, E. Beth, G. Giraldo, 1972, Journal of the National Cancer Institute.

Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis

J. Sierra, C. Vogel, L. Schwartzberg, 2010 .

Trastuzumab Monotherapy

C. Vogel, 2004, Breast Cancer Research and Treatment.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A Howell, A. Howell, A. Buzdar, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of gemcltablne in patients with metastatic breast cancer

M. Blackstein, C. Vogel, J. Cowan, 1997 .

Adjuvant docetaxel for node-positive breast cancer.

Marek Pawlicki, John Hainsworth, Matthieu Rupin, 2005, The New England journal of medicine.

Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

D. Castro, C. Vogel, E. Orenberg, 1998 .

A phase II tolerability trial of neoadjuvant docetaxel with carboplatin and capecitabine in locally advanced breast cancer

S. Franco, C. Vogel, E. Tan-chiu, 2011 .

Treatment of experimental allergic encephalomyelitis in the rabbit.

D. Paty, C. Vogel, R. Kibler, 1972, Archives of neurology.

Cyclophosphamide, adriamycin and 5-fluorouracil (CAF) alternating with a cycle-active regimen in metastatic breast cancer: A randomized southeastern cancer study group trial

J. Lefante, C. Vogel, D. East, 1981 .

Clinical trials of combination chemotherapy with BCNU and vincristine in the treatment of malignant melanoma in Uganda

C. Vogel, A. Primack, D. Dhru, 1973, Cancer.

Mechanisms of levamisole‐induced granulocytopenia in breast cancer patients

E. Sugarbaker, C. Vogel, A. Miller, 1980, American journal of hematology.

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

A. Buzdar, H. Burger, P. LoRusso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial of high‐dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature

S. Hilsenbeck, V. Cairns, C. Vogel, 1988, Cancer.

Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis.

C. Vogel, M. Woenckhaus, B. Salzberger, 2008, Rheumatology.

Liver cell dysplasia: a premalignant condition

C. Vogel, P. Anthony, L. Barker, 1973, Journal of clinical pathology.

Pneumocystis carinii pneumonia.

V. Devita, C. Vogel, R. Powell, 1968, Annals of internal medicine.

Aspergillus lobar pneumonia.

V. Devita, C. Vogel, R. Young, 1969, JAMA.

Needle biopsy in pseudocystis carinii pneumonia.

V. Devita, C. Vogel, R. Powell, 1969, Radiology.

Systemic cancer therapy: four decades of progress and some personal perspectives.

C. Vogel, 1990, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

Serologic diagnosis of active toxoplasmosis complicating malignant diseases. Usefulness of IgM antibodies and gel‐diffusion

C. Vogel, A. Gelderman, M. Lunde, 1970, Cancer.

Toxoplasma serology in patients with malignant diseases of the reticuloendothelial system

C. Vogel, M. Lunde, 1969, Cancer.

Phase II clinical trials of BCNU )NSC-409962) and bleomycin (NSC-125066) in the treatment of Kaposi's sarcoma.

C. Vogel, T. Toya, A. Primack, 1973, Cancer chemotherapy reports.

Treatment of Kaposi's sarcoma with actinomycin‐D and cyclophosphamide: Results of a randomtzed cltnical trial

C. Vogel, S. Kyalwazi, John F. A. Taylor, 1971 .

Treatment of Kaposi's sarcoma by combination of actinomycin‐D, vincristine and imidazole carboxamide (NSC‐45388): Results of a randomized clinical trial

C. Vogel, S. Lwanga, R. Owor, 1974, International journal of cancer.

Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.

A. Bluming, C. Vogel, J. Ziegler, 1972, Journal of the National Cancer Institute.

Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma.

C. Vogel, C L Vogel, K R McIntire, 1972, Cancer research.

Response to tamoxifen in estrogen receptor‐poor metastatic breast cancer

C. Vogel, S. Thomsen, W. Voigt, 1987 .

Ectopic production of human chorionic gonadotropin in ugandan patients with hepatocellular carcinoma

G. Braunstein, C. Vogel, G. Ross, 1973, Cancer.

Glutamate dehydrogenase activity related to histopathological grade of hepatocellular carcinoma in man.

R. Glazer, C. Vogel, P. Anthony, 1974, Cancer research.

A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients

R. Simon, C. Vogel, J. Ziegler, 1975, Cancer.

Studies on levamisole--induced agranulocytosis.

L. Klassen, C. Vogel, J. Thompson, 1980, Blood.

Phase II trial of recombinant Beta (IFN-Betaser) interferon in the treatment of metastatic breast cancer

C. Vogel, S. Marcus, L. Barreras, 1988, Investigational New Drugs.

Dual HER2-targeted approaches in HER2-positive breast cancer

C. Vogel, E. Ahn, 2011, Breast Cancer Research and Treatment.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

H. Rugo, L. Amler, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

C. Vogel, M. Cobleigh, D. Slamon, 2005, Clinical breast cancer.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

S. Swain, C. Vogel, S. Wadler, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelofibrosis in chronic granulocytic leukemia.

H. Gralnick, C. Vogel, J. Harbor, 1971, Blood.

Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?

C. Vogel, R. Mahtani, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

E. Winer, C. Shapiro, N. Robert, 2004, Seminars in oncology.

Acupuncture for the management of hot flashes in women with early stage breast cancer treated with tamoxifen or an aromatase inhibitor: A pilot study of efficacy, safety and feasibility

S. Franco, C. Vogel, E. Tan-chiu, 2005 .

Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?

C. Vogel, G. Lopes, S. Glück, 2012, Current Oncology Reports.

Immunological Studies in Ugandan Patients with Hepatocellular Carcinoma

C. Vogel, L. Barker, A. Primack, 1973, British medical journal.

Burkitt's tumor in the United States

J. Bennett, C. Vogel, P. Carbone, 1969, Cancer.

Monotherapy of metastatic breast cancer: a review of newer agents.

C. Vogel, J. Nabholtz, C. L. Vogel, 1999, The oncologist.

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

D. Elashoff, R. Hermann, C. Vogel, 2009 .

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

C. Vogel, S. Chia, F. Muggia, 2007, Clinical breast cancer.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

E. Winer, R. Gelman, L. Harris, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

B. Wiens, C. Vogel, S. Tjulandin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Peter A Kaufman, K. Bloom, H. Rugo, 2014, Cancer.

JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations

B. Ljung, E. Winer, E. Perez, 2006 .

Toremifene for breast cancer: a review of 20 years of data.

C. Vogel, C. Capers, M. Johnston, 2014, Clinical breast cancer.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Dan Lu, Amita Joshi, Patricia M. LoRusso, 2012, Cancer Chemotherapy and Pharmacology.

Correlation between estrogen receptors and response to nonhormonal chemotherapy in metastatic breast cancer

C. Vogel, W. Voigt, T. Umsawasdi, 1981 .

Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma.

V. Devita, R. Adamson, C. Vogel, 1972, Cancer chemotherapy reports.

Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.

C. Presant, C. Vogel, F. Ostroy, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.

C. Vogel, J. Carpenter, R. Weiner, 1986, Cancer treatment reports.

Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid.

C. Vogel, F. Valeriote, G. Clamon, 1985, Cancer research.

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer

C. Vogel, R. Mahtani, 2019, Cancer management and research.

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy.

C. Vogel, M. Troner, D. East, 1978, Cancer treatment reports.

Adjuvant Docetaxel plus Doxorubicin and Cyclophosphamide for Node-Positive Breast Cancer

A. Howell, J. Hainsworth, J. Mackey, 2005 .

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

V. Georgoulias, C. Vogel, L. Alland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer

J. Lefante, C. Vogel, J. Carpenter, 1983, Breast Cancer Research and Treatment.

Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience

C. Vogel, Alejandra T. Perez, C. Frankel, 2002, Cancer investigation.

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

M. Birkner, H. Burris, C. Vogel, 2009 .

Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.

S Michiels, M Buyse, S Marguet, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Hepatitis B virus infection and primary hepatocellular carcinoma.

C. Vogel, P. Anthony, L. Barker, 1977, Journal of the National Cancer Institute.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

J. Hainsworth, J. Mackey, D. Walde, 2013, The Lancet. Oncology.

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

C. Vogel, T. Ambros, A. Montero, 2015, Breast cancer : basic and clinical research.

Trastuzumab plus chemotherapy: convincing survival benefit or not?

C. Vogel, E. Tan-chiu, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life.

C. Hudis, J. Gralow, C. Vogel, 2005, Clinical breast cancer.

Hepatitis-associated Antigen and Antibody in Uganda: Correlation of Serological Testing with Histopathology

C. Vogel, P. Anthony, L. Barker, 1972, British medical journal.

Effects of high dose raloxifene in selected patients with advanced breast carcinoma

G. Sledge, C. Vogel, F. Cohen, 2000, Cancer.

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.

C. Vogel, A. Stein, R. Mahtani, 2009, Clinical therapeutics.

High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”.

C. Vogel, A. Stein, R. Mahtani, 2009 .

Consensus on Medical Treatment of Metastatic Breast Cancer

M. Stockler, H. Burstein, J. Bonneterre, 2003, Breast Cancer Research and Treatment.

Phase II study of oral etoposide for patients with advanced breast cancer

B. Trock, S. Swain, C. Vogel, 1995, Cancer.

Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer

J. Hainsworth, J. Mackey, T. Pintér, 2010 .

Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.

H. Linden, H. Rugo, B. Overmoyer, 2021 .

Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study

H. Linden, H. Rugo, B. Overmoyer, 2021 .

First line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with herceptin (trastuzumab, humanized anti-HER2 antibody)

C. Vogel, 2000 .

Burkittʼs tumor in the United States

J. Bennett, C. Vogel, P. Carbone, 1969 .

Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer serum with elevated orosomucoid (alpha 1-acid glycoprotein) levels.

C. Vogel, D. Cheresh, D. Lopez, 1982, Journal of the National Cancer Institute.

Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer.

J. Mackey, C. Vogel, Miguel Martín, 2007, Breast.

Clinical Experience with Trastuzumab (Herceptin)

S. Franco, C. Vogel, S. Franco, 2003, The breast journal.

Chemotherapy of extensive large cell and adenocarcinoma of the lung. A randomized trial in 210 patients

C. Vogel, C. Mountain, M. Cohen, 1980, Cancer.

Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: The Southeastern Cancer Study Group experience

A. Ketcham, C. Vogel, A. Bartolucci, 1983, Breast Cancer Research and Treatment.

Liver celldysplasia: apremalignant condition

C. Vogel, P. Anthony, L. Barker, 1973 .

Ultrastructural survey of primary liver cell carcinomas from Uganda.

C. Vogel, T. S. Tralka, G. O'Conor, 1972, Journal of the National Cancer Institute.

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

C. Vogel, L. Fehrenbacher, S. Jones, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to oophorectomy after tamoxifen failure in a premenopausal patient.

C. Vogel, A. Kalman, T. Thompson, 1982, Cancer treatment reports.

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

N. Robert, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer

S. Hilsenbeck, C. Vogel, S. Thomsen, 1984, Breast Cancer Research and Treatment.

Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer

S. Franco, H. Rugo, C. Vogel, 2007, Breast Cancer Research and Treatment.

Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

H. Rugo, M. Goetz, S. Badve, 2020, Clinical breast cancer.

Response to tamoxifen in estrogen receptor-poor metastatic breast cancer.

C. Vogel, S. Thomsen, W. Voigt, 1987, Cancer.

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.

M. Birkner, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

lighttheneedforresearchdesignedtobetterdefinethecon- textinwhichfishoilmaybenefitpatientswithcoronaryartery disease.

J. Mackey, J. Mcanulty, C. Vogel, 2017 .

Management of Kaposi’s Sarcoma

C. Vogel, 1981 .

Management of Kaposi's sarcoma. Chemotherapy I.

C. Vogel, 1981, Antibiotics and chemotherapy.

Rivanol precipitation technique for the detection of alpha-feto-protein.

C. Vogel, K. Mcintire, I. Patel, 1972, Journal of Laboratory and Clinical Medicine.

Phase II evaluation of fludarabine in patients with metastatic breast cancer: a Southeastern Cancer Study Group trial.

C. Vogel, J. Carpenter, G. Wang, 1986, Cancer treatment reports.

Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer

A. Buzdar, J. Ingle, C. Vogel, 2012, Cancer.

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

C. Vogel, Michael T. Nguyen, A. Sandoval-Leon, 2022, Journal of Medical Case Reports.

Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.

C. Vogel, H. Hochster, S. Burman, 2001, The oncologist.

Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

L. Pusztai, W. Gradishar, R. Nanda, 2017 .

Patterns of anthracycline retention modulation in human tumor cells.

C. Vogel, A. Krishan, K. Sridhar, 1987, Cytometry.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.

Third consensus on medical treatment of metastatic breast cancer.

M. Stockler, M. Gnant, H. Burstein, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.

C. Vogel, M. O'Rourke, H. Hochster, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Response to tamoxifen in estrogen receptor‐poor metastatic breast cancer

C. Vogel, S. Thomsen, W. Voigt, 1987, Cancer.

Treatment of metastatic breast cancer.

C. Vogel, C. Vogel, 1991, Seminars in oncology nursing.

Reliability of estrogen receptors in predicting hormonal responsiveness in treatment of metastatic breast cancer.

C. Vogel, S. Thomsen, W. Voigt, 1979, The Journal of the Florida Medical Association.

Reliability of clinical estrogen receptor assays performed on tumor tissue biopsied from sites previously treated with radiotherapy.

E. Sugarbaker, C. Vogel, S. Thomsen, 1979, Surgery.

Suppression of experimental allergic encephalomyelitis by NSC 82196, a new imidazole carboxamide derivative.

C. Vogel, R. Lisak, M. Kies, 1969, Cancer research.

Fluorescence in situ hybridization (FISH) may accurately select patients likely to benefit from herceptin monotherapy

C. Vogel, M. Cobleigh, D. Tripathy, 2001 .

Enhanced Suppression of Experimental Allergic Encephalomyelitis by Combination Chemotherapy with Duazomycin-A and 6-Mercaptopurine∗

C. Vogel, P. Calabresi, 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Southeastern Cancer Study Group: breast cancer studies 1972-1982.

J. Lefante, C. Perez, C. Vogel, 1983, International journal of radiation oncology, biology, physics.